ondasdechoque.org
PT-BR

Lateral elbow tendinopathy · Randomized trial · 1996

Does shockwave ease long-lasting tennis elbow pain?

In this trial of 100 people with tennis elbow lasting over a year, three sessions of focused shockwave eased pain. Night pain fell from about 33 to about 7 out of 100 by 24 weeks after treatment, while it stayed near 30 with a very low dose. 48% had a good or excellent result, versus 6%.

Helped more than a very low dose
adults with tennis elbow for over a year
100
sessions, one a week
3
weeks of follow-up after treatment
24

Good to know: Published in 1996; followed for 24 weeks after treatment.

Rompe JD, Hope C, Küllmer K, et al. The Journal of Bone and Joint Surgery. British Volume, 1996 · Read the paper ↗

How this study worked

Full-dose shockwave50 peopleVery low dose50 peopleShockwaveSham
People were assigned by lot. One group had a sham: the same-looking treatment without the active waves. Each dot is one person.

Conceptual animation: a focused front converges, then spreads. Not to scale. Tap the field to send a pulse.

What happened

Pain at night

0–100 pain scale · start, then weeks after the last session

Full-dose shockwaveVery low dose

Night pain fell from about 33 to 7 out of 100 with full-dose shockwave, and stayed around 30 to 35 with the very low dose.
Show the numbers
GroupStart3624 wk
Full-dose shockwave32.513.27.77.3
Very low dose29.934.635.132.5

The treatment

Full-dose shockwave

Focused, once a week for 3 weeks

Focused wavesMeet at a focal zone below the skin
Sessions
3, one a week
Pulses
1,000 per session
Strength
0.08mJ/mm² · 3 per second
Numbing
None
Device
Siemens Osteostar

Compared with: A very low dose: 10 pulses a session at the same strength, also 3 sessions

Settings are what each study used, not a prescription.

Who took part

100 adults with tennis elbow for more than a year that had not improved with other treatment, 50 in each group.

Full-dose shockwave50 people
Very low dose50 people

Side effects

The paper did not list side effects; it says everyone could tolerate the discomfort of treatment.

All the numbers and the full appraisal

Every reported result

FROM THE FULL PAPER

The results, in numbers.

100 adults reportedly randomized (50 per group), with lateral epicondyle pain >12 months, unsuccessful conservative care within the previous six months, and at least two positive provocation tests. The methods also say 115 patients were treated over three years and 15 discontinued in the first six weeks before stating that 100 completed the course; timing relative to randomization is unclear. The reported duration ranges (10 to 120 months in Group I, 10 to 46 in Group II) start below the stated 12-month entry criterion.

Full-dose focused ESWT (Group I)50randomized

The report says 100 patients were randomly assigned, 50 per group, after describing 115 treated patients and 15 who discontinued in the first six weeks. It does not clarify whether those 15 left before randomization or were excluded after allocation; outcome-specific follow-up denominators are not stated.

Very-low-dose shock-wave control (Group II)50randomized

The report says 100 patients were randomly assigned, 50 per group, after describing 115 treated patients and 15 who discontinued in the first six weeks. It does not clarify whether those 15 left before randomization or were excluded after allocation; outcome-specific follow-up denominators are not stated.

Visual analogue scale (0=no pain, 100=maximum pain)24 reported outcomes
01
Immediately after treatment

Night pain

Visual analogue scale (0=no pain, 100=maximum pain) VAS points, mean (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
34.6
Very-low-dose shock-wave control (Group II)
31.2
0100 VAS points, mean (SD)
Night pain · Immediately after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—32.5 (SD 17.3)34.6 (SD 15.8)
Very-low-dose shock-wave control (Group II)—29.9 (SD 15.6)31.2 (SD 16)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Group I mean was 34.6 (SD 15.8) and Group II 31.2 (SD 16) immediately after treatment; table p value for the between-group comparison: >0.05. The paper reports lower pain in Group I at each post-treatment follow-up from week 3 onward, but gives no between-group mean difference or confidence interval.

Analysis details and source

Baseline is the table’s pre-treatment (−6 weeks) measurement; outcome-specific denominators are not reported. P values are cross-group comparisons at each assessment, not within-arm change tests.

02
3 weeks after treatment

Night pain

Visual analogue scale (0=no pain, 100=maximum pain) VAS points, mean (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
13.2
Very-low-dose shock-wave control (Group II)
34.6
0100 VAS points, mean (SD)
Night pain · 3 weeks after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—32.5 (SD 17.3)13.2 (SD 9.9)
Very-low-dose shock-wave control (Group II)—29.9 (SD 15.6)34.6 (SD 17.6)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Group I mean was 13.2 (SD 9.9) and Group II 34.6 (SD 17.6) at 3 weeks after treatment; table p value for the between-group comparison: <0.001. The paper reports lower pain in Group I at each post-treatment follow-up from week 3 onward, but gives no between-group mean difference or confidence interval.

Analysis details and source

Baseline is the table’s pre-treatment (−6 weeks) measurement; outcome-specific denominators are not reported. P values are cross-group comparisons at each assessment, not within-arm change tests.

03
6 weeks after treatment

Night pain

Visual analogue scale (0=no pain, 100=maximum pain) VAS points, mean (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
7.7
Very-low-dose shock-wave control (Group II)
35.1
0100 VAS points, mean (SD)
Night pain · 6 weeks after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—32.5 (SD 17.3)7.7 (SD 8.8)
Very-low-dose shock-wave control (Group II)—29.9 (SD 15.6)35.1 (SD 18.1)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Group I mean was 7.7 (SD 8.8) and Group II 35.1 (SD 18.1) at 6 weeks after treatment; table p value for the between-group comparison: <0.001. The paper reports lower pain in Group I at each post-treatment follow-up from week 3 onward, but gives no between-group mean difference or confidence interval.

Analysis details and source

Baseline is the table’s pre-treatment (−6 weeks) measurement; outcome-specific denominators are not reported. P values are cross-group comparisons at each assessment, not within-arm change tests.

04
24 weeks after treatment

Night pain

Visual analogue scale (0=no pain, 100=maximum pain) VAS points, mean (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
7.3
Very-low-dose shock-wave control (Group II)
32.5
0100 VAS points, mean (SD)
Night pain · 24 weeks after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—32.5 (SD 17.3)7.3 (SD 8.7)
Very-low-dose shock-wave control (Group II)—29.9 (SD 15.6)32.5 (SD 17.4)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Group I mean was 7.3 (SD 8.7) and Group II 32.5 (SD 17.4) at 24 weeks after treatment; table p value for the between-group comparison: <0.001. The paper reports lower pain in Group I at each post-treatment follow-up from week 3 onward, but gives no between-group mean difference or confidence interval.

Analysis details and source

Baseline is the table’s pre-treatment (−6 weeks) measurement; outcome-specific denominators are not reported. P values are cross-group comparisons at each assessment, not within-arm change tests.

05
Immediately after treatment

Resting pain

Visual analogue scale (0=no pain, 100=maximum pain) VAS points, mean (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
37.3
Very-low-dose shock-wave control (Group II)
27.3
0100 VAS points, mean (SD)
Resting pain · Immediately after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—33.3 (SD 22)37.3 (SD 24.2)
Very-low-dose shock-wave control (Group II)—25.8 (SD 14.7)27.3 (SD 16.8)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Group I mean was 37.3 (SD 24.2) and Group II 27.3 (SD 16.8) immediately after treatment; table p value for the between-group comparison: >0.05. The paper reports lower pain in Group I at each post-treatment follow-up from week 3 onward, but gives no between-group mean difference or confidence interval.

Analysis details and source

Baseline is the table’s pre-treatment (−6 weeks) measurement; outcome-specific denominators are not reported. P values are cross-group comparisons at each assessment, not within-arm change tests.

06
3 weeks after treatment

Resting pain

Visual analogue scale (0=no pain, 100=maximum pain) VAS points, mean (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
15.3
Very-low-dose shock-wave control (Group II)
30.8
0100 VAS points, mean (SD)
Resting pain · 3 weeks after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—33.3 (SD 22)15.3 (SD 10.5)
Very-low-dose shock-wave control (Group II)—25.8 (SD 14.7)30.8 (SD 19.4)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Group I mean was 15.3 (SD 10.5) and Group II 30.8 (SD 19.4) at 3 weeks after treatment; table p value for the between-group comparison: <0.001. The paper reports lower pain in Group I at each post-treatment follow-up from week 3 onward, but gives no between-group mean difference or confidence interval.

Analysis details and source

Baseline is the table’s pre-treatment (−6 weeks) measurement; outcome-specific denominators are not reported. P values are cross-group comparisons at each assessment, not within-arm change tests.

07
6 weeks after treatment

Resting pain

Visual analogue scale (0=no pain, 100=maximum pain) VAS points, mean (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
14.8
Very-low-dose shock-wave control (Group II)
33.8
0100 VAS points, mean (SD)
Resting pain · 6 weeks after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—33.3 (SD 22)14.8 (SD 15.5)
Very-low-dose shock-wave control (Group II)—25.8 (SD 14.7)33.8 (SD 19.8)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Group I mean was 14.8 (SD 15.5) and Group II 33.8 (SD 19.8) at 6 weeks after treatment; table p value for the between-group comparison: <0.001. The paper reports lower pain in Group I at each post-treatment follow-up from week 3 onward, but gives no between-group mean difference or confidence interval.

Analysis details and source

Baseline is the table’s pre-treatment (−6 weeks) measurement; outcome-specific denominators are not reported. P values are cross-group comparisons at each assessment, not within-arm change tests.

08
24 weeks after treatment

Resting pain

Visual analogue scale (0=no pain, 100=maximum pain) VAS points, mean (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
11.9
Very-low-dose shock-wave control (Group II)
33.3
0100 VAS points, mean (SD)
Resting pain · 24 weeks after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—33.3 (SD 22)11.9 (SD 14.7)
Very-low-dose shock-wave control (Group II)—25.8 (SD 14.7)33.3 (SD 22)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Group I mean was 11.9 (SD 14.7) and Group II 33.3 (SD 22) at 24 weeks after treatment; table p value for the between-group comparison: <0.001. The paper reports lower pain in Group I at each post-treatment follow-up from week 3 onward, but gives no between-group mean difference or confidence interval.

Analysis details and source

Baseline is the table’s pre-treatment (−6 weeks) measurement; outcome-specific denominators are not reported. P values are cross-group comparisons at each assessment, not within-arm change tests.

09
Immediately after treatment

Pressure pain

Visual analogue scale (0=no pain, 100=maximum pain) VAS points, mean (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
63.6
Very-low-dose shock-wave control (Group II)
60.7
0100 VAS points, mean (SD)
Pressure pain · Immediately after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—58.8 (SD 16.5)63.6 (SD 16)
Very-low-dose shock-wave control (Group II)—55.6 (SD 13.1)60.7 (SD 16.7)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Group I mean was 63.6 (SD 16) and Group II 60.7 (SD 16.7) immediately after treatment; table p value for the between-group comparison: >0.05. The paper reports lower pain in Group I at each post-treatment follow-up from week 3 onward, but gives no between-group mean difference or confidence interval.

Analysis details and source

Baseline is the table’s pre-treatment (−6 weeks) measurement; outcome-specific denominators are not reported. P values are cross-group comparisons at each assessment, not within-arm change tests.

10
3 weeks after treatment

Pressure pain

Visual analogue scale (0=no pain, 100=maximum pain) VAS points, mean (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
33.1
Very-low-dose shock-wave control (Group II)
60.2
0100 VAS points, mean (SD)
Pressure pain · 3 weeks after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—58.8 (SD 16.5)33.1 (SD 11.7)
Very-low-dose shock-wave control (Group II)—55.6 (SD 13.1)60.2 (SD 17)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Group I mean was 33.1 (SD 11.7) and Group II 60.2 (SD 17) at 3 weeks after treatment; table p value for the between-group comparison: <0.001. The paper reports lower pain in Group I at each post-treatment follow-up from week 3 onward, but gives no between-group mean difference or confidence interval.

Analysis details and source

Baseline is the table’s pre-treatment (−6 weeks) measurement; outcome-specific denominators are not reported. P values are cross-group comparisons at each assessment, not within-arm change tests.

11
6 weeks after treatment

Pressure pain

Visual analogue scale (0=no pain, 100=maximum pain) VAS points, mean (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
26.9
Very-low-dose shock-wave control (Group II)
59.8
0100 VAS points, mean (SD)
Pressure pain · 6 weeks after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—58.8 (SD 16.5)26.9 (SD 14)
Very-low-dose shock-wave control (Group II)—55.6 (SD 13.1)59.8 (SD 15.3)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Group I mean was 26.9 (SD 14) and Group II 59.8 (SD 15.3) at 6 weeks after treatment; table p value for the between-group comparison: <0.001. The paper reports lower pain in Group I at each post-treatment follow-up from week 3 onward, but gives no between-group mean difference or confidence interval.

Analysis details and source

Baseline is the table’s pre-treatment (−6 weeks) measurement; outcome-specific denominators are not reported. P values are cross-group comparisons at each assessment, not within-arm change tests.

12
24 weeks after treatment

Pressure pain

Visual analogue scale (0=no pain, 100=maximum pain) VAS points, mean (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
22.6
Very-low-dose shock-wave control (Group II)
58.1
0100 VAS points, mean (SD)
Pressure pain · 24 weeks after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—58.8 (SD 16.5)22.6 (SD 15.8)
Very-low-dose shock-wave control (Group II)—55.6 (SD 13.1)58.1 (SD 15.2)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Group I mean was 22.6 (SD 15.8) and Group II 58.1 (SD 15.2) at 24 weeks after treatment; table p value for the between-group comparison: <0.001. The paper reports lower pain in Group I at each post-treatment follow-up from week 3 onward, but gives no between-group mean difference or confidence interval.

Analysis details and source

Baseline is the table’s pre-treatment (−6 weeks) measurement; outcome-specific denominators are not reported. P values are cross-group comparisons at each assessment, not within-arm change tests.

13
Immediately after treatment

Thomsen test pain

Visual analogue scale (0=no pain, 100=maximum pain) VAS points, mean (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
54.7
Very-low-dose shock-wave control (Group II)
52.8
0100 VAS points, mean (SD)
Thomsen test pain · Immediately after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—53.2 (SD 16.1)54.7 (SD 16.4)
Very-low-dose shock-wave control (Group II)—49.2 (SD 13)52.8 (SD 14.1)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Group I mean was 54.7 (SD 16.4) and Group II 52.8 (SD 14.1) immediately after treatment; table p value for the between-group comparison: >0.05. The paper reports lower pain in Group I at each post-treatment follow-up from week 3 onward, but gives no between-group mean difference or confidence interval.

Analysis details and source

Baseline is the table’s pre-treatment (−6 weeks) measurement; outcome-specific denominators are not reported. P values are cross-group comparisons at each assessment, not within-arm change tests.

14
3 weeks after treatment

Thomsen test pain

Visual analogue scale (0=no pain, 100=maximum pain) VAS points, mean (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
29
Very-low-dose shock-wave control (Group II)
53.5
0100 VAS points, mean (SD)
Thomsen test pain · 3 weeks after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—53.2 (SD 16.1)29 (SD 16.4)
Very-low-dose shock-wave control (Group II)—49.2 (SD 13)53.5 (SD 14.2)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Group I mean was 29 (SD 16.4) and Group II 53.5 (SD 14.2) at 3 weeks after treatment; table p value for the between-group comparison: <0.001. The paper reports lower pain in Group I at each post-treatment follow-up from week 3 onward, but gives no between-group mean difference or confidence interval.

Analysis details and source

Baseline is the table’s pre-treatment (−6 weeks) measurement; outcome-specific denominators are not reported. P values are cross-group comparisons at each assessment, not within-arm change tests.

15
6 weeks after treatment

Thomsen test pain

Visual analogue scale (0=no pain, 100=maximum pain) VAS points, mean (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
25.2
Very-low-dose shock-wave control (Group II)
57.4
0100 VAS points, mean (SD)
Thomsen test pain · 6 weeks after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—53.2 (SD 16.1)25.2 (SD 15.4)
Very-low-dose shock-wave control (Group II)—49.2 (SD 13)57.4 (SD 12.8)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Group I mean was 25.2 (SD 15.4) and Group II 57.4 (SD 12.8) at 6 weeks after treatment; table p value for the between-group comparison: <0.001. The paper reports lower pain in Group I at each post-treatment follow-up from week 3 onward, but gives no between-group mean difference or confidence interval.

Analysis details and source

Baseline is the table’s pre-treatment (−6 weeks) measurement; outcome-specific denominators are not reported. P values are cross-group comparisons at each assessment, not within-arm change tests.

16
24 weeks after treatment

Thomsen test pain

Visual analogue scale (0=no pain, 100=maximum pain) VAS points, mean (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
21.2
Very-low-dose shock-wave control (Group II)
50.5
0100 VAS points, mean (SD)
Thomsen test pain · 24 weeks after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—53.2 (SD 16.1)21.2 (SD 16.4)
Very-low-dose shock-wave control (Group II)—49.2 (SD 13)50.5 (SD 16.9)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Group I mean was 21.2 (SD 16.4) and Group II 50.5 (SD 16.9) at 24 weeks after treatment; table p value for the between-group comparison: <0.001. The paper reports lower pain in Group I at each post-treatment follow-up from week 3 onward, but gives no between-group mean difference or confidence interval.

Analysis details and source

Baseline is the table’s pre-treatment (−6 weeks) measurement; outcome-specific denominators are not reported. P values are cross-group comparisons at each assessment, not within-arm change tests.

17
Immediately after treatment

Resisted finger-extension pain

Visual analogue scale (0=no pain, 100=maximum pain) VAS points, mean (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
54.8
Very-low-dose shock-wave control (Group II)
55.4
0100 VAS points, mean (SD)
Resisted finger-extension pain · Immediately after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—55.8 (SD 16.9)54.8 (SD 17.6)
Very-low-dose shock-wave control (Group II)—51.8 (SD 14.9)55.4 (SD 12.9)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Group I mean was 54.8 (SD 17.6) and Group II 55.4 (SD 12.9) immediately after treatment; table p value for the between-group comparison: >0.05. The paper reports lower pain in Group I at each post-treatment follow-up from week 3 onward, but gives no between-group mean difference or confidence interval.

Analysis details and source

Baseline is the table’s pre-treatment (−6 weeks) measurement; outcome-specific denominators are not reported. P values are cross-group comparisons at each assessment, not within-arm change tests.

18
3 weeks after treatment

Resisted finger-extension pain

Visual analogue scale (0=no pain, 100=maximum pain) VAS points, mean (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
29.8
Very-low-dose shock-wave control (Group II)
60.9
0100 VAS points, mean (SD)
Resisted finger-extension pain · 3 weeks after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—55.8 (SD 16.9)29.8 (SD 11.1)
Very-low-dose shock-wave control (Group II)—51.8 (SD 14.9)60.9 (SD 12.2)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Group I mean was 29.8 (SD 11.1) and Group II 60.9 (SD 12.2) at 3 weeks after treatment; table p value for the between-group comparison: <0.001. The paper reports lower pain in Group I at each post-treatment follow-up from week 3 onward, but gives no between-group mean difference or confidence interval.

Analysis details and source

Baseline is the table’s pre-treatment (−6 weeks) measurement; outcome-specific denominators are not reported. P values are cross-group comparisons at each assessment, not within-arm change tests.

19
6 weeks after treatment

Resisted finger-extension pain

Visual analogue scale (0=no pain, 100=maximum pain) VAS points, mean (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
24
Very-low-dose shock-wave control (Group II)
62.8
0100 VAS points, mean (SD)
Resisted finger-extension pain · 6 weeks after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—55.8 (SD 16.9)24 (SD 13.8)
Very-low-dose shock-wave control (Group II)—51.8 (SD 14.9)62.8 (SD 12.3)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Group I mean was 24 (SD 13.8) and Group II 62.8 (SD 12.3) at 6 weeks after treatment; table p value for the between-group comparison: <0.001. The paper reports lower pain in Group I at each post-treatment follow-up from week 3 onward, but gives no between-group mean difference or confidence interval.

Analysis details and source

Baseline is the table’s pre-treatment (−6 weeks) measurement; outcome-specific denominators are not reported. P values are cross-group comparisons at each assessment, not within-arm change tests.

20
24 weeks after treatment

Resisted finger-extension pain

Visual analogue scale (0=no pain, 100=maximum pain) VAS points, mean (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
20.1
Very-low-dose shock-wave control (Group II)
60.1
0100 VAS points, mean (SD)
Resisted finger-extension pain · 24 weeks after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—55.8 (SD 16.9)20.1 (SD 13.3)
Very-low-dose shock-wave control (Group II)—51.8 (SD 14.9)60.1 (SD 14.8)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Group I mean was 20.1 (SD 13.3) and Group II 60.1 (SD 14.8) at 24 weeks after treatment; table p value for the between-group comparison: <0.001. The paper reports lower pain in Group I at each post-treatment follow-up from week 3 onward, but gives no between-group mean difference or confidence interval.

Analysis details and source

Baseline is the table’s pre-treatment (−6 weeks) measurement; outcome-specific denominators are not reported. P values are cross-group comparisons at each assessment, not within-arm change tests.

21
Immediately after treatment

Chair-test pain

Visual analogue scale (0=no pain, 100=maximum pain) VAS points, mean (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
48.7
Very-low-dose shock-wave control (Group II)
52.9
0100 VAS points, mean (SD)
Chair-test pain · Immediately after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—46 (SD 18.1)48.7 (SD 19.9)
Very-low-dose shock-wave control (Group II)—48.9 (SD 17)52.9 (SD 16.7)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Group I mean was 48.7 (SD 19.9) and Group II 52.9 (SD 16.7) immediately after treatment; table p value for the between-group comparison: >0.05. The paper reports lower pain in Group I at each post-treatment follow-up from week 3 onward, but gives no between-group mean difference or confidence interval.

Analysis details and source

Baseline is the table’s pre-treatment (−6 weeks) measurement; outcome-specific denominators are not reported. P values are cross-group comparisons at each assessment, not within-arm change tests.

22
3 weeks after treatment

Chair-test pain

Visual analogue scale (0=no pain, 100=maximum pain) VAS points, mean (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
24.8
Very-low-dose shock-wave control (Group II)
51.2
0100 VAS points, mean (SD)
Chair-test pain · 3 weeks after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—46 (SD 18.1)24.8 (SD 17.5)
Very-low-dose shock-wave control (Group II)—48.9 (SD 17)51.2 (SD 15.1)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Group I mean was 24.8 (SD 17.5) and Group II 51.2 (SD 15.1) at 3 weeks after treatment; table p value for the between-group comparison: <0.001. The paper reports lower pain in Group I at each post-treatment follow-up from week 3 onward, but gives no between-group mean difference or confidence interval.

Analysis details and source

Baseline is the table’s pre-treatment (−6 weeks) measurement; outcome-specific denominators are not reported. P values are cross-group comparisons at each assessment, not within-arm change tests.

23
6 weeks after treatment

Chair-test pain

Visual analogue scale (0=no pain, 100=maximum pain) VAS points, mean (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
20.9
Very-low-dose shock-wave control (Group II)
53.8
0100 VAS points, mean (SD)
Chair-test pain · 6 weeks after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—46 (SD 18.1)20.9 (SD 14.8)
Very-low-dose shock-wave control (Group II)—48.9 (SD 17)53.8 (SD 14)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Group I mean was 20.9 (SD 14.8) and Group II 53.8 (SD 14) at 6 weeks after treatment; table p value for the between-group comparison: <0.001. The paper reports lower pain in Group I at each post-treatment follow-up from week 3 onward, but gives no between-group mean difference or confidence interval.

Analysis details and source

Baseline is the table’s pre-treatment (−6 weeks) measurement; outcome-specific denominators are not reported. P values are cross-group comparisons at each assessment, not within-arm change tests.

24
24 weeks after treatment

Chair-test pain

Visual analogue scale (0=no pain, 100=maximum pain) VAS points, mean (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
16.7
Very-low-dose shock-wave control (Group II)
52.7
0100 VAS points, mean (SD)
Chair-test pain · 24 weeks after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—46 (SD 18.1)16.7 (SD 14.4)
Very-low-dose shock-wave control (Group II)—48.9 (SD 17)52.7 (SD 14.6)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Group I mean was 16.7 (SD 14.4) and Group II 52.7 (SD 14.6) at 24 weeks after treatment; table p value for the between-group comparison: <0.001. The paper reports lower pain in Group I at each post-treatment follow-up from week 3 onward, but gives no between-group mean difference or confidence interval.

Analysis details and source

Baseline is the table’s pre-treatment (−6 weeks) measurement; outcome-specific denominators are not reported. P values are cross-group comparisons at each assessment, not within-arm change tests.

Night pain1 reported outcome
25
24 weeks after treatment

Night pain percentage change

Night pain percentage change, mean (SD)

Night pain percentage change · 24 weeks after treatment · means
GroupnBaselineReported change
Full-dose focused ESWT (Group I)——-78.9 (SD 22.4)
Very-low-dose shock-wave control (Group II)——4 (SD 7.3)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Mean percentage change: Group I -78.9% (SD 22.4) and Group II 4% (SD 7.3), reported p<0.001 between groups. Negative percentages mean pain decreased; positive percentages mean it increased.

Analysis details and source

The table reports the group means and p value but no between-group estimate or interval; do not treat the p value as an effect size.

Resting pain1 reported outcome
26
24 weeks after treatment

Resting pain percentage change

Resting pain percentage change, mean (SD)

Resting pain percentage change · 24 weeks after treatment · means
GroupnBaselineReported change
Full-dose focused ESWT (Group I)——-68.1 (SD 18.5)
Very-low-dose shock-wave control (Group II)——21.9 (SD 18.1)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Mean percentage change: Group I -68.1% (SD 18.5) and Group II 21.9% (SD 18.1), reported p<0.001 between groups. Negative percentages mean pain decreased; positive percentages mean it increased.

Analysis details and source

The table reports the group means and p value but no between-group estimate or interval; do not treat the p value as an effect size.

Pressure pain1 reported outcome
27
24 weeks after treatment

Pressure pain percentage change

Pressure pain percentage change, mean (SD)

Pressure pain percentage change · 24 weeks after treatment · means
GroupnBaselineReported change
Full-dose focused ESWT (Group I)——-64.5 (SD 18.1)
Very-low-dose shock-wave control (Group II)——-4.3 (SD 10.6)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Mean percentage change: Group I -64.5% (SD 18.1) and Group II -4.3% (SD 10.6), reported p<0.001 between groups. Negative percentages mean pain decreased; positive percentages mean it increased.

Analysis details and source

The table reports the group means and p value but no between-group estimate or interval; do not treat the p value as an effect size.

Thomsen test1 reported outcome
28
24 weeks after treatment

Thomsen test percentage change

Thomsen test percentage change, mean (SD)

Thomsen test percentage change · 24 weeks after treatment · means
GroupnBaselineReported change
Full-dose focused ESWT (Group I)——-61.2 (SD 20.8)
Very-low-dose shock-wave control (Group II)——-4.4 (SD 9.4)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Mean percentage change: Group I -61.2% (SD 20.8) and Group II -4.4% (SD 9.4), reported p<0.001 between groups. Negative percentages mean pain decreased; positive percentages mean it increased.

Analysis details and source

The table reports the group means and p value but no between-group estimate or interval; do not treat the p value as an effect size.

Finger extension1 reported outcome
29
24 weeks after treatment

Finger extension percentage change

Finger extension percentage change, mean (SD)

Finger extension percentage change · 24 weeks after treatment · means
GroupnBaselineReported change
Full-dose focused ESWT (Group I)——-63.3 (SD 19.7)
Very-low-dose shock-wave control (Group II)——8.5 (SD 8)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Mean percentage change: Group I -63.3% (SD 19.7) and Group II 8.5% (SD 8), reported p<0.001 between groups. Negative percentages mean pain decreased; positive percentages mean it increased.

Analysis details and source

The table reports the group means and p value but no between-group estimate or interval; do not treat the p value as an effect size.

Chair test1 reported outcome
30
24 weeks after treatment

Chair test percentage change

Chair test percentage change, mean (SD)

Chair test percentage change · 24 weeks after treatment · means
GroupnBaselineReported change
Full-dose focused ESWT (Group I)——-65.7 (SD 19.1)
Very-low-dose shock-wave control (Group II)——-0.3 (SD 7.8)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Mean percentage change: Group I -65.7% (SD 19.1) and Group II -0.3% (SD 7.8), reported p<0.001 between groups. Negative percentages mean pain decreased; positive percentages mean it increased.

Analysis details and source

The table reports the group means and p value but no between-group estimate or interval; do not treat the p value as an effect size.

Vigorimeter with source-described four-level category (1=equal bilateral strength; higher categories indicate larger reduction versus unaffected side)4 reported outcomes
31
Immediately after treatment

Relative grip-strength category

Vigorimeter with source-described four-level category (1=equal bilateral strength; higher categories indicate larger reduction versus unaffected side) mean category (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
2.7
Very-low-dose shock-wave control (Group II)
2.6
14 mean category (SD)
Relative grip-strength category · Immediately after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—2.4 (SD 1)2.7 (SD 1.1)
Very-low-dose shock-wave control (Group II)—2.4 (SD 0.8)2.6 (SD 0.9)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Table III reports means 2.7 (SD 1.1) in Group I and 2.6 (SD 0.9) in Group II; p<0.05. Lower category values indicate more symmetrical strength; the paper calls this grip strength but describes an ordinal relative-side classification.

Analysis details and source

This is the mean of the paper’s 1–4 relative-side category, not dynamometer pressure in physical units. Outcome-specific denominators are not reported.

32
3 weeks after treatment

Relative grip-strength category

Vigorimeter with source-described four-level category (1=equal bilateral strength; higher categories indicate larger reduction versus unaffected side) mean category (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
1.8
Very-low-dose shock-wave control (Group II)
2.4
14 mean category (SD)
Relative grip-strength category · 3 weeks after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—2.4 (SD 1)1.8 (SD 0.8)
Very-low-dose shock-wave control (Group II)—2.4 (SD 0.8)2.4 (SD 0.7)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Table III reports means 1.8 (SD 0.8) in Group I and 2.4 (SD 0.7) in Group II; p=<0.001. Lower category values indicate more symmetrical strength; the paper calls this grip strength but describes an ordinal relative-side classification.

Analysis details and source

This is the mean of the paper’s 1–4 relative-side category, not dynamometer pressure in physical units. Outcome-specific denominators are not reported.

33
6 weeks after treatment

Relative grip-strength category

Vigorimeter with source-described four-level category (1=equal bilateral strength; higher categories indicate larger reduction versus unaffected side) mean category (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
1.7
Very-low-dose shock-wave control (Group II)
2.4
14 mean category (SD)
Relative grip-strength category · 6 weeks after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—2.4 (SD 1)1.7 (SD 0.7)
Very-low-dose shock-wave control (Group II)—2.4 (SD 0.8)2.4 (SD 0.8)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Table III reports means 1.7 (SD 0.7) in Group I and 2.4 (SD 0.8) in Group II; p=<0.001. Lower category values indicate more symmetrical strength; the paper calls this grip strength but describes an ordinal relative-side classification.

Analysis details and source

This is the mean of the paper’s 1–4 relative-side category, not dynamometer pressure in physical units. Outcome-specific denominators are not reported.

34
24 weeks after treatment

Relative grip-strength category

Vigorimeter with source-described four-level category (1=equal bilateral strength; higher categories indicate larger reduction versus unaffected side) mean category (SD)

BaselineFollow-up
Full-dose focused ESWT (Group I)
2
Very-low-dose shock-wave control (Group II)
2.4
14 mean category (SD)
Relative grip-strength category · 24 weeks after treatment · means
GroupnBaselineFollow-up
Full-dose focused ESWT (Group I)—2.4 (SD 1)2 (SD 1)
Very-low-dose shock-wave control (Group II)—2.4 (SD 0.8)2.4 (SD 1)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Table III reports means 2 (SD 1) in Group I and 2.4 (SD 1) in Group II; p=<0.001. Lower category values indicate more symmetrical strength; the paper calls this grip strength but describes an ordinal relative-side classification.

Analysis details and source

This is the mean of the paper’s 1–4 relative-side category, not dynamometer pressure in physical units. Outcome-specific denominators are not reported.

Roles and Maudsley four-category overall rating12 reported outcomes
35
3 weeks after treatment

Excellent overall rating

Roles and Maudsley four-category overall rating participants

Full-dose focused ESWT (Group I)11 / 50
Very-low-dose shock-wave control (Group II)0 / 50

Excellent: 11/50 in Group I and 0/50 in Group II. No category-specific between-group effect estimate or p value is reported in the table.

Analysis details and source

The four categories are mutually exclusive and exhaustive at each timepoint. The study does not report a comparative estimate for these category counts.

36
3 weeks after treatment

Good overall rating

Roles and Maudsley four-category overall rating participants

Full-dose focused ESWT (Group I)16 / 50
Very-low-dose shock-wave control (Group II)10 / 50

Good: 16/50 in Group I and 10/50 in Group II. No category-specific between-group effect estimate or p value is reported in the table.

Analysis details and source

The four categories are mutually exclusive and exhaustive at each timepoint. The study does not report a comparative estimate for these category counts.

37
3 weeks after treatment

Acceptable overall rating

Roles and Maudsley four-category overall rating participants

Full-dose focused ESWT (Group I)18 / 50
Very-low-dose shock-wave control (Group II)16 / 50

Acceptable: 18/50 in Group I and 16/50 in Group II. No category-specific between-group effect estimate or p value is reported in the table.

Analysis details and source

The four categories are mutually exclusive and exhaustive at each timepoint. The study does not report a comparative estimate for these category counts.

38
3 weeks after treatment

Poor overall rating

Roles and Maudsley four-category overall rating participants

Full-dose focused ESWT (Group I)5 / 50
Very-low-dose shock-wave control (Group II)24 / 50

Poor: 5/50 in Group I and 24/50 in Group II. No category-specific between-group effect estimate or p value is reported in the table.

Analysis details and source

The four categories are mutually exclusive and exhaustive at each timepoint. The study does not report a comparative estimate for these category counts.

39
6 weeks after treatment

Excellent overall rating

Roles and Maudsley four-category overall rating participants

Full-dose focused ESWT (Group I)10 / 50
Very-low-dose shock-wave control (Group II)0 / 50

Excellent: 10/50 in Group I and 0/50 in Group II. No category-specific between-group effect estimate or p value is reported in the table.

Analysis details and source

The four categories are mutually exclusive and exhaustive at each timepoint. The study does not report a comparative estimate for these category counts.

40
6 weeks after treatment

Good overall rating

Roles and Maudsley four-category overall rating participants

Full-dose focused ESWT (Group I)16 / 50
Very-low-dose shock-wave control (Group II)6 / 50

Good: 16/50 in Group I and 6/50 in Group II. No category-specific between-group effect estimate or p value is reported in the table.

Analysis details and source

The four categories are mutually exclusive and exhaustive at each timepoint. The study does not report a comparative estimate for these category counts.

41
6 weeks after treatment

Acceptable overall rating

Roles and Maudsley four-category overall rating participants

Full-dose focused ESWT (Group I)18 / 50
Very-low-dose shock-wave control (Group II)10 / 50

Acceptable: 18/50 in Group I and 10/50 in Group II. No category-specific between-group effect estimate or p value is reported in the table.

Analysis details and source

The four categories are mutually exclusive and exhaustive at each timepoint. The study does not report a comparative estimate for these category counts.

42
6 weeks after treatment

Poor overall rating

Roles and Maudsley four-category overall rating participants

Full-dose focused ESWT (Group I)6 / 50
Very-low-dose shock-wave control (Group II)34 / 50

Poor: 6/50 in Group I and 34/50 in Group II. No category-specific between-group effect estimate or p value is reported in the table.

Analysis details and source

The four categories are mutually exclusive and exhaustive at each timepoint. The study does not report a comparative estimate for these category counts.

43
24 weeks after treatment

Excellent overall rating

Roles and Maudsley four-category overall rating participants

Full-dose focused ESWT (Group I)11 / 50
Very-low-dose shock-wave control (Group II)0 / 50

Excellent: 11/50 in Group I and 0/50 in Group II. No category-specific between-group effect estimate or p value is reported in the table.

Analysis details and source

The four categories are mutually exclusive and exhaustive at each timepoint. The study does not report a comparative estimate for these category counts.

44
24 weeks after treatment

Good overall rating

Roles and Maudsley four-category overall rating participants

Full-dose focused ESWT (Group I)13 / 50
Very-low-dose shock-wave control (Group II)3 / 50

Good: 13/50 in Group I and 3/50 in Group II. No category-specific between-group effect estimate or p value is reported in the table.

Analysis details and source

The four categories are mutually exclusive and exhaustive at each timepoint. The study does not report a comparative estimate for these category counts.

45
24 weeks after treatment

Acceptable overall rating

Roles and Maudsley four-category overall rating participants

Full-dose focused ESWT (Group I)21 / 50
Very-low-dose shock-wave control (Group II)12 / 50

Acceptable: 21/50 in Group I and 12/50 in Group II. No category-specific between-group effect estimate or p value is reported in the table.

Analysis details and source

The four categories are mutually exclusive and exhaustive at each timepoint. The study does not report a comparative estimate for these category counts.

46
24 weeks after treatment

Poor overall rating

Roles and Maudsley four-category overall rating participants

Full-dose focused ESWT (Group I)5 / 50
Very-low-dose shock-wave control (Group II)35 / 50

Poor: 5/50 in Group I and 35/50 in Group II. No category-specific between-group effect estimate or p value is reported in the table.

Analysis details and source

The four categories are mutually exclusive and exhaustive at each timepoint. The study does not report a comparative estimate for these category counts.

Roles and Maudsley rating, source-defined combined category3 reported outcomes
47
3 weeks after treatment

Good or excellent overall outcome

Roles and Maudsley rating, source-defined combined category participants

Full-dose focused ESWT (Group I)27 / 50
Very-low-dose shock-wave control (Group II)10 / 50

27/50 versus 10/50 had good/excellent status at 3 weeks. The 24-week counts reproduce the article’s abstract proportions (48% vs 6%); no between-group effect estimate is reported in the paper.

Analysis details and source

Derived transparently by summing the source Table IV excellent and good rows; this is a post hoc combined category for charting and does not imply a pre-specified primary endpoint.

48
6 weeks after treatment

Good or excellent overall outcome

Roles and Maudsley rating, source-defined combined category participants

Full-dose focused ESWT (Group I)26 / 50
Very-low-dose shock-wave control (Group II)6 / 50

26/50 versus 6/50 had good/excellent status at 6 weeks. The 24-week counts reproduce the article’s abstract proportions (48% vs 6%); no between-group effect estimate is reported in the paper.

Analysis details and source

Derived transparently by summing the source Table IV excellent and good rows; this is a post hoc combined category for charting and does not imply a pre-specified primary endpoint.

49
24 weeks after treatment

Good or excellent overall outcome

Roles and Maudsley rating, source-defined combined category participants

Full-dose focused ESWT (Group I)24 / 50
Very-low-dose shock-wave control (Group II)3 / 50

24/50 versus 3/50 had good/excellent status at 24 weeks. The 24-week counts reproduce the article’s abstract proportions (48% vs 6%); no between-group effect estimate is reported in the paper.

Analysis details and source

Derived transparently by summing the source Table IV excellent and good rows; this is a post hoc combined category for charting and does not imply a pre-specified primary endpoint.

How treatment was delivered
Device and modality

Electromagnetic focused shock-wave generator integrated into Siemens Osteostar mobile fluoroscopy unit.

Active dose

Group I received 1,000 impulses/session at 0.08 mJ/mm², for 3 sessions (3,000 total impulses).

Control condition

Group II received 10 impulses/session at the same 0.08 mJ/mm², for 3 sessions (30 total); a minimal-dose exposure, not an inert no-pulse sham.

Application method

Three weekly sessions at 3 Hz, each lasting 20–30 min; treatment at anterior lateral epicondyle and three surrounding points 1.5–2 cm away. C-arm centered on lateral epicondyle; water-filled cylinder and ultrasound gel for coupling.

Anesthesia and co-interventions

No local anesthesia. No other treatment during the 6 weeks before ESWT or during the treatment course.

Follow-up and outcomes

Review at 3, 6, and 24 weeks after the final session; Table I additionally reports a 0-week post-treatment measurement. Pain VAS 0–100; four provocation tests; bilateral grip-strength category; Roles–Maudsley rating. No formal primary outcome is clearly specified.

HARMS & TOLERABILITY

The article gives no systematic adverse-event table or arm-specific event counts. It states that no participant was unable to tolerate shock-wave discomfort. A separate author statement about >500 previously treated patients is not study-specific.

LIMITS OF THE ANALYSIS

115 patients were initially treated; 15 discontinued in the first six weeks. The report does not identify their reasons, group allocation, or whether they left before randomization.

The randomization method, allocation concealment, assessor masking, and intention-to-treat handling are not described.

The control received 30 impulses in total versus 3,000 in the active group; the difference in treatment sensation may threaten masking, which was not formally assessed.

No between-group effect sizes or confidence intervals are given for the pain, grip, or categorical outcomes, despite multiple measurements and tests.

Follow-up ends at 24 weeks after treatment.

The full text was preserved as a reader snapshot. The two figures are equipment/application illustrations and were not retrievable; their captions were read and do not contain numeric outcome data.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • 115 patients were initially treated; 15 discontinued in the first six weeks. The report does not identify their reasons, group allocation, or whether they left before randomization.
  • The randomization method, allocation concealment, assessor masking, and intention-to-treat handling are not described.
  • The control received 30 impulses in total versus 3,000 in the active group; the difference in treatment sensation may threaten masking, which was not formally assessed.
  • No between-group effect sizes or confidence intervals are given for the pain, grip, or categorical outcomes, despite multiple measurements and tests.
  • Follow-up ends at 24 weeks after treatment.
  • The full text was preserved as a reader snapshot. The two figures are equipment/application illustrations and were not retrievable; their captions were read and do not contain numeric outcome data.
Research review

Source-linked critical reading

Randomized comparative clinical trial

Reading depthMaterial consulted
Technical source record

Full author-uploaded article text snapshot read through the References, including all four tables and figure captions; table values checked against reader text. Figure image retrieval was unavailable, but both figures are illustrative device/application images rather than outcome plots. Snapshot SHA-256 ef1945cb9181e62bc9d5b5a6550928bf44b9e7142693e3830418bc7b3647b68f.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Design and allocation

The authors describe a prospective, controlled study with random assignment of 100 patients to two groups of 50. The report does not explain sequence generation, concealment, or assessor masking. It first states 115 patients were treated and 15 discontinued in the initial six weeks before describing the 100-person random allocation, leaving the timing and handling of these losses unclear.

Participants

Adults had lateral epicondyle pain for >12 months, unsuccessful conservative treatment in the preceding six months, and at least two positive provocation tests. Mean age was 43.9 years in Group I and 41.9 in Group II; reported mean symptom durations were 24.8 and 21.9 months. The reported duration ranges (10–120 and 10–46 months) start below the 12-month entry criterion.

Intervention

Group I received three weekly sessions, each with 1,000 focused electromagnetic impulses at 0.08 mJ/mm² (3,000 total). The Siemens Osteostar C-arm was centered on the lateral epicondyle, with treatment at the anterior epicondyle and three points 1.5–2 cm around it. No local anesthesia was used; each session lasted 20–30 minutes.

Comparator

Group II received 10 impulses per session at the same energy density (30 total). This is a minimal-dose control with sensory exposure, not an inert zero-impulse sham. The paper does not report a formal test of whether participants or assessors guessed allocation.

Outcomes and follow-up

Pain was measured on a 0–100 VAS at night, at rest and during four provocation tests (pressure, Thomsen, finger extension and chair tests). Table I gives means and SDs at pre-treatment (−6 weeks) and 0, 3, 6 and 24 weeks after treatment. Additional outcomes were percentage pain change at 24 weeks, relative grip-strength category, and four Roles–Maudsley categories at 3, 6 and 24 weeks. A single prespecified primary outcome is not identified.

Between-group findings

Table I reports p>0.05 for all pain tests before treatment and immediately after treatment, then p<0.001 for each test at 3, 6 and 24 weeks. Group I means were lower than Group II at these later assessments. At 24 weeks, good/excellent ratings were 24/50 (48%) versus 3/50 (6%), and acceptable ratings were 21/50 (42%) versus 12/50 (24%). These are large reported contrasts, but the paper supplies no confidence intervals or comparative effect estimates for these outcomes.

Harms and tolerability

No adverse-event table is provided. The authors state that no patient was unable to tolerate the discomfort of treatment; the report does not give systematic event counts or safety denominators. Its statement that no complications had been seen in more than 500 previously treated patients is prior clinical experience, not a safety result from this 100-person study.

Limitations and uncertainty

The 15 early discontinuations among 115 initially treated patients are not allocated by group, and their relation to randomization is unclear. There is no participant-flow diagram, no explicit allocation method, no assessor-masking description, and no clear intention-to-treat analysis. The comparator received only 1% of the active impulses, potentially compromising masking. Follow-up is limited to 24 weeks. Outcomes have no between-group effect sizes or confidence intervals; the many pain tests and timepoints also raise multiplicity concerns.

Applicability

The findings concern people with very chronic (>12-month) lateral elbow pain after unsuccessful conservative treatment, using a specific focused electromagnetic device and a highly asymmetric low-dose control. They do not establish effects for recent-onset symptoms, radial devices, different doses, or modern sham-controlled protocols.

What stronger research should do

A stronger trial should register a clear primary outcome, randomize before treatment with concealed allocation, publish a participant-flow diagram and analyze all randomized participants. A credible sham should be tested for masking, and investigators should report group-specific adverse events, absolute effects with confidence intervals, and a multiplicity plan.

THE ORIGINAL SOURCE

Read the original article.

Analgesic effect of extracorporeal shock-wave therapy on chronic tennis elbow.

Rompe JD, Hope C, Küllmer K, Heine J, Bürger R. · The Journal of bone and joint surgery. British volume · 1996

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →